stockrow
Friday 6 November 2026
Export LIVN’s income statement to Excel — free account
LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
90.21
0.93
−1.02%
Follow LIVN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
8 | 8 | 6 | 4 |
+8 more TTM periods Free account |
| 15.50% | 15.40% | 9.54% | (19.24%) | ||
| 7.44% | 7.33% | 4.22% | (9.49%) | ||
ROIC |
9.14% | 10.63% | 12.52% | 13.24% | |
Return on Tangible Assets |
36.78% | 31.88% | 21.12% | (45.22%) | |
Average Days of Receivables |
57.26 | 57.37 | 58.38 | 56.80 | |
Free Cash Flow per Share |
2.47 | 2.83 | 3.08 | 3.31 | |
Free Cash Flow |
136.35 | 155.59 | 168.32 | 180.57 | |
Capital Expenditures |
(101.55) | (93.67) | (77.27) | (73.77) | |
| Other line items | |||||
Cash ROIC |
6.10% | 7.29% | 8.26% | 8.16% | |
Accounts Receivable Turnover |
6.73 | 6.52 | 6.65 | 6.79 | |
Accounts Payable Turnover |
4.97 | 4.93 | 4.99 | 5.37 | |
Inventory Turnover |
2.81 | 2.78 | 2.92 | 2.87 | |
Average Days of Payables |
80.50 | 80.38 | 77.64 | 79.12 | |
Days of Inventory on Hand |
133.97 | 134.20 | 129.61 | 134.13 | |
Tax Rate |
0.64 | 0.76 | (0.12) | 0.10 | |
Research and Development Expense of Revenue |
14.08% | 14.48% | 14.41% | 13.38% | |
Selling, General and Administrative Expense of Revenue |
39.82% | 39.66% | 39.29% | 39.54% | |
Share Based Compensation of Revenue |
3.26% | 3.02% | 2.57% | 2.61% | |
Interest Coverage |
5.11 | 5.43 | 4.55 | 4.05 | |
Operating CF/Net income |
1.21 | 1.32 | 2.29 | (1.05) | |
Depreciation/Fixed assets |
0.30 | 0.31 | 0.32 | 0.34 | |
Capex/Depreciation |
(1.17) | (1.10) | (0.93) | (0.89) | |
Revenue per Share |
27.35 | 26.77 | 26.21 | 25.45 | |
Operating CF per Share |
4.32 | 4.53 | 4.49 | 4.66 | |
Capex per Share |
(1.84) | (1.70) | (1.41) | (1.35) | |
Capex to Sales |
0.07 | 0.06 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026